Albiges L - Search Results

1

[Metastatic renal cell carcinoma: Management of toxicities of combinations].

Joly F, Michot JM, Dourthe LM, Fléchon A, Mahammedi H, Maillet D, Mouillet G, Pouessel D, Rolland F, Topart D, Albiges L. Joly F, et al. Among authors: albiges l. Bull Cancer. 2022 Jul-Aug;109(7-8):844-861. doi: 10.1016/j.bulcan.2022.04.019. Epub 2022 Jun 21. Bull Cancer. 2022. PMID: 35738914 Review. French.

2

[New drugs in metastatic castration-resistant prostate cancer].

Albiges L, Loriot Y, Gross-Goupil M, de La Motte Rouge T, Blesius A, Escudier B, Massard C, Fizazi K. Albiges L, et al. Bull Cancer. 2010 Jan;97(1):149-59. doi: 10.1684/bdc.2009.1023. Bull Cancer. 2010. PMID: 20022854 French.

3

Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography.

Lassau N, Koscielny S, Albiges L, Chami L, Benatsou B, Chebil M, Roche A, Escudier BJ. Lassau N, et al. Among authors: albiges l. Clin Cancer Res. 2010 Feb 15;16(4):1216-25. doi: 10.1158/1078-0432.CCR-09-2175. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145174

4

Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma.

Escudier B, Albiges L. Escudier B, et al. Among authors: albiges l. Drugs. 2011 Jun 18;71(9):1179-91. doi: 10.2165/11591410-000000000-00000. Drugs. 2011. PMID: 21711062 Review.

5

Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.

Albiges L, Salem M, Rini B, Escudier B. Albiges L, et al. Hematol Oncol Clin North Am. 2011 Aug;25(4):813-33. doi: 10.1016/j.hoc.2011.04.006. Hematol Oncol Clin North Am. 2011. PMID: 21763969 Review.

6

Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.

Sadeghi S, Albiges L, Wood LS, Black SL, Gilligan TD, Dreicer R, Garcia JA, Escudier BJ, Rini BI. Sadeghi S, et al. Among authors: albiges l. Cancer. 2012 Jul 1;118(13):3277-82. doi: 10.1002/cncr.26666. Epub 2011 Dec 2. Cancer. 2012. PMID: 22139966 Free article.

7

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.

Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, Duclos B, Geoffrois L, Rolland F, Guillot A, Laguerre B, Legouffe E, Kohser F, Dietrich PY, Theodore CA, Escudier B. Albiges L, et al. J Clin Oncol. 2012 Feb 10;30(5):482-7. doi: 10.1200/JCO.2011.37.2516. Epub 2012 Jan 9. J Clin Oncol. 2012. PMID: 22231040

8

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.

Albiges L, Chamming's F, Duclos B, Stern M, Motzer RJ, Ravaud A, Camus P. Albiges L, et al. Ann Oncol. 2012 Aug;23(8):1943-1953. doi: 10.1093/annonc/mds115. Epub 2012 Jun 11. Ann Oncol. 2012. PMID: 22689175 Free article. Review.

9

Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?

Albiges L, Molinie V, Escudier B. Albiges L, et al. Oncologist. 2012;17(8):1051-62. doi: 10.1634/theoncologist.2012-0038. Epub 2012 Jul 17. Oncologist. 2012. PMID: 22807514 Free PMC article. Review.

10

Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.

Iacovelli R, Lanoy E, Albiges L, Escudier B. Iacovelli R, et al. Among authors: albiges l. BJU Int. 2012 Dec;110(11):1747-53. doi: 10.1111/j.1464-410X.2012.11518.x. Epub 2012 Oct 26. BJU Int. 2012. PMID: 23106948 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

332 results

Search Page

Filters